Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Multiple Myeloma 3Burkitt Lymphoma 3Lymphoma, Follicular 2Plasmablastic Lymphoma 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Effusion 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Intraocular Lymphoma 1Hodgkin Disease 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 4Etoposide 4Cyclophosphamide 4Vincristine 3Prednisone 3Doxorubicin 3liposomal doxorubicin 2varlilumab 1prednylidene 1pomalidomide 1fialuridine 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Primary Effusion × pomalidomide × Lymphoid × Clear all
NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡